Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement

SAN DIEGO, CA–(Marketwire – Sep 23, 2011) – Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution? System agreement with Apollo Hospitals, one of Asia’s largest private healthcare groups, to offer the technology initially at select cosmetic surgery centers in India.

“At Apollo Hospitals, we pride ourselves on introducing the latest technological medical advancements,” said Dr. Prathap C. Reddy, founder and Chairman of Apollo Hospitals Group. “The alliance with Cytori has the potential to revolutionize the delivery of personalized cell therapy in India. The Cytori Celution? System represents best-in-class regenerative medicine technology that enables surgeons’ access to the power of the patient’s own regenerative cells as real-time therapy for cosmetic surgery as well as a variety of other ischemic conditions.”

Apollo Hospitals is a core customer around which Cytori can build a successful commercial business in India. This agreement follows a clinical evaluation of Celution?-based soft tissue procedures performed by Apollo. More information about Apollo Hospitals Group can be found at

About Cytori
Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution? System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource? product line is sold globally for cell banking and research applications. Our PureGraftT products are available in North America and Europe for fat grafting procedures.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, such as building a successful commercial business in India, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Click to view original post